Basic and clinical studies demonstrate that stress and depression are associated with atrophy and loss of neurons and glia, which contribute to the decreased size and function of limbic brain regions that control mood and depression, including the prefrontal cortex and hippocampus. Here, we review findings that suggest that opposing effects of stress and/or depression and antidepressants on neurotrophic factor expression and signaling partly explain these effects. We also discuss recent reports that suggest a possible role for glycogen synthase kinase 3 and upstream wingless (Wnt)-frizzled (Fz) signaling pathways in mood disorders. New studies also demonstrate that the rapid antidepressant actions of NMDA receptor antagonists are associated with activation of glutamate transmission and induction of synaptogenesis, providing novel targets for a new generation of fast-acting, more efficacious therapeutic agents.
Introduction
Depression and stress-related mood disorders impact approximately 17% of the population, resulting in enormous personal suffering, as well as social and economic burden [1] [2] [3] . The neurobiology underlying depression has not yet been fully identified, but is thought to result from molecular and cellular abnormalities that interact with genetic and environmental factors [4] . This complexity and heterogeneity have made it difficult to define, diagnose and treat this widespread illness. Currently available antidepressants, although widely prescribed for depression and other mood and anxiety-related illnesses, have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates (only one-third respond to the first drug prescribed, and up to two-thirds after multiple trials, often taking months to years) [5] . This is particularly problematic for an illness that is associated with high rates of suicide.
Typical antidepressants acutely block the reuptake or breakdown of the monoamines 5-hydroxytryptamine (5-HT or serotonin) and norepinephrine ( Figure 1) , with 5-HT selective reuptake inhibitors (SSRIs) representing the most highly prescribed medication for depression and related mood disorders. This acute mechanism of action led to the monoamine hypothesis of depression, but the time lag for treatment response indicates that slow onset adaptations of downstream signaling pathways and regulation of target genes underlie the therapeutic actions of antidepressants (Figure 1 ). These signaling pathways and target genes in turn result in regulation of multiple physiological processes, including neuroplasticity, neuroprotection and neurogenesis in the adult brain [4, 6] .
Significant efforts have been directed toward the characterization of the downstream targets of antidepressant treatment, with the promise of identifying novel therapeutic targets. Several signaling pathways and targets have been identified and we focus here on a few of the bestcharacterized and validated systems, including the neurotrophic factor, Wnt and glycogen synthase kinase 3 (GSK3) pathways. We also discuss the functional consequences of these systems in the context of the damaging effects of chronic stress, including atrophy and loss of neurons and glia, effects also observed in brain imaging and postmortem studies of patients with depression.
In addition to advances made in understanding the actions of typical antidepressants and, conversely, the damaging effects of stress and depression, recent studies have begun to elucidate the mechanisms underlying a novel class of antidepressants, NMDA receptor antagonists. These agents, notably ketamine, produce a rapid antidepressant action, an effect not seen with any previous agent, in patients with severe depression who are resistant to typical antidepressants [7, 8] . Moreover, this rapid, efficacious response occurs via a completely different pathway, involving increased glutamate transmission and induction of synaptogenesis [9] . Here, we also discuss this pathway and related ketamine-induced signaling pathways.
Together, these findings underscore the importance of characterizing the intracellular signaling pathways that underlie the actions of antidepressants, as well as stress and depression. Importantly, comparison of typical antidepressants with novel, rapid-acting NMDA antagonists also highlights the difference between agents that act on neuromodulatory systems (i.e. monoamines) compared with those that act on the major excitatory neurotransmitter system 
